An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with someone more experienced may help them feel more confident in managing their condition, with self-reported psychological benefits for both people in the pairing. That’s according to five-year…

Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called…

Tweet I have made the point that the action of anti-CD20 antibodies is probably in the blood and not in the CNS. A trial of double/treble dose of ocrelizumab to help get into the CNS failed to show any extra benefit over the standard dose.…

MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Chris Pero as June’s … Continue reading → Source:…

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global…

Tweet This is a question I have posed and answered. Are they the same? You know that you can have them as an infusion or at home and they inhibit relapses and new lesion formation and this class of drug has become one of the…